Literature DB >> 23133183

Diagnosis, staging and treatment of patients with non-small cell lung cancer for the surgeon.

Ayesha S Bryant1, Robert J Cerfolio.   

Abstract

This article covers the risk factors, diagnostic tools, staging methods/modalities and treatment for patients with non-small cell lung cancer (NSCLC). Also presented is the new 7th edition American Joint Cancer Committee (AJCC) TNM classification for staging of NSCLC and a recommended treatment algorithm.

Entities:  

Keywords:  Lung cancer; Surgery; Treatment for NSCLC

Year:  2010        PMID： 23133183      PMCID： PMC3452752          DOI： 10.1007/s12262-009-0086-4

Source DB:  PubMed          Journal:  Indian J Surg        ISSN： 0973-9793            Impact factor:   0.656


  36 in total

1.  Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study.

Authors:  R Hubbard; A Venn; S Lewis; J Britton
Journal:  Am J Respir Crit Care Med       Date:  2000-01       Impact factor: 21.405

2.  Preoperative staging of non-small-cell lung cancer with positron-emission tomography.

Authors:  R M Pieterman; J W van Putten; J J Meuzelaar; E L Mooyaart; W Vaalburg; G H Koëter; V Fidler; J Pruim; H J Groen
Journal:  N Engl J Med       Date:  2000-07-27       Impact factor: 91.245

3.  Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer.

Authors:  T Bury; A Dowlati; P Paulus; J L Corhay; R Hustinx; B Ghaye; M Radermecker; P Rigo
Journal:  Eur Respir J       Date:  1997-11       Impact factor: 16.671

4.  Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial.

Authors:  Harm van Tinteren; Otto S Hoekstra; Egbert F Smit; Jan H A M van den Bergh; Ad J M Schreurs; Roland A L M Stallaert; Piet C M van Velthoven; Emile F I Comans; Fred W Diepenhorst; Paul Verboom; Johan C van Mourik; Pieter E Postmus; Maarten Boers; Gerrit J J Teule
Journal:  Lancet       Date:  2002-04-20       Impact factor: 79.321

5.  Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.

Authors:  Giorgio V Scagliotti; Roldano Fossati; Valter Torri; Lucio Crinò; Giuseppe Giaccone; Giovanni Silvano; Massimo Martelli; Maurizia Clerici; Francesco Cognetti; Maurizio Tonato
Journal:  J Natl Cancer Inst       Date:  2003-10-01       Impact factor: 13.506

6.  Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53.

Authors:  M F Denissenko; A Pao; M Tang; G P Pfeifer
Journal:  Science       Date:  1996-10-18       Impact factor: 47.728

Review 7.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

Review 8.  Epidemiology of lung cancer.

Authors:  Anthony J Alberg; Jonathan M Samet
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

9.  Percutaneous radiofrequency ablation for inoperable non-small cell lung cancer and metastases: preliminary report.

Authors:  Jeong Min Lee; Gong Yong Jin; S Nahum Goldberg; Yong Cheol Lee; Gyung Ho Chung; Young Min Han; Sang Yong Lee; Chong Soo Kim
Journal:  Radiology       Date:  2003-11-26       Impact factor: 11.105

10.  Intracostal sutures decrease the pain of thoracotomy.

Authors:  Robert J Cerfolio; Theolynn N Price; Ayesha S Bryant; Cynthia Sale Bass; Alfred A Bartolucci
Journal:  Ann Thorac Surg       Date:  2003-08       Impact factor: 4.330
View more
  2 in total

1.  Assessment of thoracic vasculature in patients with central bronchogenic carcinoma by unenhanced magnetic resonance angiography: comparison between 2D free-breathing TrueFISP, 2D breath-hold TrueFISP and 3D respiratory-triggered SPACE.

Authors:  Lili Wang; Peng Lv; Shuohui Yang; Mengsu Zeng; Jiang Lin
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

2.  Application of diffusion kurtosis imaging and 18F-FDG PET in evaluating the subtype, stage and proliferation status of non-small cell lung cancer.

Authors:  Pengyang Feng; Zehua Shao; Bai Dong; Ting Fang; Zhun Huang; Ziqiang Li; Fangfang Fu; Yaping Wu; Wei Wei; Jianmin Yuan; Yang Yang; Zhe Wang; Meiyun Wang
Journal:  Front Oncol       Date:  2022-09-30       Impact factor: 5.738
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.